Search results for "CINV"
showing 4 items of 4 documents
Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving mode…
2011
PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT(3)) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids. METHODS: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting …
Onkoloģiskās ķīmijterapijas izraisītas neiroloģiskās blakusparādības, to atkarība no pacienta dzīvildzes prognostiskajiem rādītājiem, ĶMI, dzimuma un…
2017
Virsrakst: Onkoloģiskās ķīmijterapijas izraisītas neiroloģiskās blakusparādības, to atkarība no pacienta dzīvildzes prognostiskajiem rādītājiem, ĶMI, dzimuma un ķīmijterapijas veida, iespēja blaknes mazināt. Priekšvēsture: Neiroloģiskās blakusparādības ir samērā biežas un nopietnas ķīmijterapijas blaknes. Ķīmijterapija var izraisīt pastāvīgus nopietnus bojājumus nervu sistēmā, ko reizumis nākas novērst, pārtraucot ķīmijterapiju. Neiroloģiskās blaknes bieži paliek neievērotas, atšķirībā no citām vieglāk pamanāmām. Agrīna iejaukšanās varētu mazināt neiroloģiskās blaknes, tas palīdzētu veikt pilnvērtīgu ķīmijterapijas kursu un labāk ārstēt vēzi. Mērķis: Mērķis ir noskaidrot, vai vēža pacienta …
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri eve…
2021
OBJECTIVE: The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects. Chemotherapy-induced nausea and vomiting (CINV) are amongst the most troublesome side effects that impair patients’ adherence to treatments and their quality of life (QoL). NEPA (Akynzeo®), is an oral fixed-dose combination of netupitant [a neurokinin-1 receptor antagonist (NK1RA), 300 mg] and palonosetron [(5-hydroxytryptamine (serotonin or 5HT) type3 receptor antagonist (5HT3RA), 0.5 mg] which has been shown to be effective in preventing CINV. PATIENTS AND METHODS: This prospective study started before…
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
2019
Purpose: Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients, receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK 1 receptor antagonist (NK 1 -RA), a 5-HT 3 receptor antagonist (5HT 3 -RA), and dexamethasone on each day of the antineoplastic treatment. NEPA is the first oral fixed-dose combination of a highly selective NK 1 -RA, netupitant, and second-generation 5HT 3 -RA, palonosetron. So far, no data has been published in literature about the efficacy of a s…